NEW YORK (Reuters Health) – An investigational formulation of azelastine and fluticasone (MP29-02) is more effective than either agent alone as intranasal therapy for moderate-to-severe seasonal allergic rhinitis (SAR), according to the pooled results of three randomized, controlled trials.
“This...